<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964405</url>
  </required_header>
  <id_info>
    <org_study_id>112016</org_study_id>
    <nct_id>NCT00964405</nct_id>
  </id_info>
  <brief_title>Phase I Study of GSK233705 in Healthy Japanese Male Subjects</brief_title>
  <official_title>Phase I Study of GSK233705- A Randomised, Double Blind, Placebo-controlled, 2-parts Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Inhaled Doses of GSK233705 From a Novel Dry Powder Device in Healthy Japanese Male Subjects -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a randomised, double blind, placebo-controlled, 2-parts study to investigate the
      safety, tolerability, and pharmacokinetics of single and repeat inhaled doses of GSK233705
      from a novel dry powder device in healthy Japanese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2008</start_date>
  <completion_date type="Actual">December 20, 2008</completion_date>
  <primary_completion_date type="Actual">December 20, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety：adverse events, vital sign, ECGs, and clinical laboratory test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PK：Cmax, tmax and AUC(0-t)</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>LAMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After randomization subjects will inhale placebo once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK233705</intervention_name>
    <description>Inhaled Long acting muscarinic receptor antagonist</description>
    <arm_group_label>LAMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy
             subjects are defined as individuals who are free from clinically significant illness
             or disease as determined by their medical history, physical examination, laboratory
             studies, and other tests.

          2. Body weight ≥ 50kg and BMI within the range 18.50-25.00kg/m2 inclusive.

          3. Non-smokers (never smoked or not smoking for &gt;6 months with &lt;10 pack years history
             (Pack years = (cigarettes per day smoked/20) x number of years smoked))

          4. Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).

          5. Clinical laboratory tests data obtained at screening meet the following:

             AST(GOT), ALT(GPT), total-bilirubin: below the upper limit of the normal ranges

          6. Normal 12-lead EGC finding at screening; QTc interval &lt;450msec

          7. A mean blood pressure lower than 140/90mmHg at screening.

          8. Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          9. Capable of using the novel dry powder inhaler.

        Exclusion Criteria:

          1. The subject has any clinically relevant abnormality on medical examination, vital
             sign, clinical laboratory test or medical history at screening in the medical opinion
             of the investigator or the subject has a medical history that is not considered as
             eligible for inclusion in this study by the investigator.

          2. The subject is currently participating in another clinical study or post-marketing
             study in which the subject is or will be exposed to an investigational or a
             non-investigational drug or device.

          3. The subject has participated in a clinical study with an investigational or a
             non-investigational drug or device during the previous 4 months.

          4. A history of breathing problems (i.e. history of asthmatic symptomatology, asthma in
             childhood).

          5. The subject has a known allergy or hypersensitivity to ipratropium bromide,
             tiotropium, atropine and any of its derivatives.

          6. The subject has a known allergy or hypersensitivity to milk protein or the excipients
             lactose monohydrate and magnesium stearate.

          7. The subject has a history or current conditions of drug abuse or alcoholism.

          8. History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink=5
             ounces (150mL) of wine or 350mL of beer or 1.5 ounces (45mL) of 80 proof distilled
             spirits) within 6 month of screening.

          9. The subject is positive for urine drug screening.

         10. The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1
             antibody.

         11. The subject has donated a unit of blood &quot;&gt;400mL&quot; within the previous 4 months or
             &quot;&gt;200mL&quot; within the previous 1 month.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/112016?search=study&amp;search_terms=112016#rs</url>
    <description>Results for study 112016 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>This study has not been published in the scientific literature.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

